Dupont Capital Management Corp Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Dupont Capital Management Corp purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIOGet Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,114 shares of the company’s stock, valued at approximately $91,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of BridgeBio Pharma by 1.0% in the first quarter. Vanguard Group Inc. now owns 9,424,112 shares of the company’s stock valued at $95,655,000 after buying an additional 92,429 shares during the period. Laurion Capital Management LP grew its stake in BridgeBio Pharma by 111.9% during the second quarter. Laurion Capital Management LP now owns 1,474,450 shares of the company’s stock worth $13,388,000 after purchasing an additional 778,535 shares during the period. Charles Schwab Investment Management Inc. grew its stake in BridgeBio Pharma by 3.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,079,082 shares of the company’s stock worth $10,953,000 after purchasing an additional 33,792 shares during the period. FMR LLC grew its stake in BridgeBio Pharma by 0.3% during the second quarter. FMR LLC now owns 980,362 shares of the company’s stock worth $8,902,000 after purchasing an additional 3,165 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in BridgeBio Pharma by 3.2% during the first quarter. Bank of New York Mellon Corp now owns 502,713 shares of the company’s stock worth $5,102,000 after purchasing an additional 15,368 shares during the period. Institutional investors and hedge funds own 96.46% of the company’s stock.

Insiders Place Their Bets

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 19,678 shares of the stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $9.40, for a total value of $184,973.20. Following the transaction, the chief financial officer now owns 341,264 shares in the company, valued at $3,207,881.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Neil Kumar sold 34,640 shares of the firm’s stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $9.40, for a total value of $325,616.00. Following the transaction, the chief executive officer now owns 4,813,197 shares in the company, valued at $45,244,051.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brian C. Stephenson sold 19,678 shares of the firm’s stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $9.40, for a total value of $184,973.20. Following the completion of the transaction, the chief financial officer now owns 341,264 shares in the company, valued at approximately $3,207,881.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 235,358 shares of company stock worth $1,899,166. Corporate insiders own 29.60% of the company’s stock.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $8.40 on Thursday. The business’s 50 day simple moving average is $8.69 and its two-hundred day simple moving average is $9.79. The firm has a market cap of $1.26 billion, a P/E ratio of -2.50 and a beta of 0.62. BridgeBio Pharma, Inc. has a 52-week low of $4.98 and a 52-week high of $12.64.

BridgeBio Pharma (NASDAQ:BBIOGet Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.09. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $6.26 million. On average, equities analysts forecast that BridgeBio Pharma, Inc. will post -3.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. decreased their target price on BridgeBio Pharma from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, BridgeBio Pharma presently has an average rating of “Buy” and a consensus price target of $23.00.

BridgeBio Pharma Profile

(Get Rating)

BridgeBio Pharma, Inc engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Further Reading

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIOGet Rating).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.